MacTel (NHOR) Registry

Trial ID:
Martin Friedlander, M.D., Ph.D.
This is an observational study to build a registry of patients with Macular telangiectasia (MacTel), a disease that affects the macula - the part of the eye that controls sharp, straight-ahead vision. The condition is characterized by slow vision loss beginning in adulthood that becomes progressively worse, but rarely leads to total blindness. There no current treatments to prevent or slow the progression of the disease.

Inclusion Criteria

Patients must:

  • Must have a confirmed clinical diagnosis of MacTel Type 2.
    Must be 18 years of age or older.

Exclusion Criteria

Patients must not:

  • Have diabetic retinopathy with 10 or more microaneurysms.
    Have any confounding ocular conditions that may complicate the evaluation of MacTel Type 2 now or in the future.

Additional Info

The MacTel Project is an international research collaboration among clinicians and bench scientists to study macular telangiectasia type 2, or MacTel. The MacTel Project aims to improve the clinical understanding of MacTel type 2, raise awareness of the disease, and identify causes and appropriate treatments.

Contact Info:

  • Clinical Research Services